ProAssurance Corporation (PRA)
NYSEFinancialsInsurance - Property & CasualtySnapshot 2026-09-04
$25.000.00%
Close 2026-07-02 · 1-day change
NYSEFinancialsInsurance - Property & CasualtySnapshot 2026-09-04
Warn: Management is running behind on a stated commitment.
ProAssurance finished its merger with The Doctors Company in June 2026. The company aims for $0.99 EPS in fiscal 2026. It improved underwriting with combined ratios falling to 109.9% in Q1 2026. Premium rate increases of 6% show pricing discipline.
The company faces soft guidance and missed Q1 EPS by 4%. Combined ratios remain high above 100%, hurting profits. Revenue is expected to shrink about 5% next year. The merger may bring integration risks and management changes.
The price is about 12% below our fair value near $28. Analysts expect about 5% revenue decline. Our view is cautious on growth but sees some value in the turnaround.
Breaks if: EPS falls below 0.99 USD per share in 2026-FY
Deliver earnings per diluted share of $0.99 for the full fiscal year 2025 as a financial performance target.
Stated as a priority in 2 of last 2 quarters. The company reported net income of $50.9 million and EPS of $0.99 for fiscal year 2025, meeting the stated EPS target. This reflects delivery on the financial performance goal.
“For the year ended December 31, 2025, net income was $50.9 million, or $0.99 per diluted share.”
“For the year ended December 31, 2025, net income was $50.9 million, or $0.99 per diluted share.”
Breaks if: merger not closed by June 30, 2026
Complete the merger with The Doctors Company, subject to regulatory approvals, by June 30, 2026 to combine scale and capabilities.
Stated as a priority in 2 of last 2 quarters. Management consistently anticipates closing the merger by June 30, 2026, with regulatory approvals received in several states but pending in California and Pennsylvania. The transaction completed on June 26, 2026, per material events, indicating delivery on this priority.
“we continue to anticipate closing the transaction by June 30, 2026”
“we continue to anticipate closing the transaction by June 30, 2026”
Breaks if: premium rate increase falls below 6% in 2026-Q1
Continue progress toward premium rate levels appropriate for challenging medical professional liability and workers’ compensation markets, maintaining underwriting discipline.
Stated as a priority in 2 of last 2 quarters. Specialty P&C renewal premium increases were 8% in 2025 and 6% in 2026-Q1, reflecting ongoing rate adequacy efforts. Retention remained stable around 83-84%. The trajectory shows continued focus with slight moderation in renewal increases, indicating delivery with some market challenges.
“Operating performance continues to demonstrate progress toward premium rate levels appropriate for the challenging conditions... We continue to forgo renewal and new business opportunities when they…”
“Operating performance continues to demonstrate progress toward premium rate levels appropriate for the challenging conditions... We continue to forgo renewal and new business opportunities when they…”
Breaks if: combined ratio rises above 109.9% in 2026-Q1
Reduce combined ratios and improve operating income across Specialty P&C and overall segments to enhance profitability.
Stated as a priority in 2 of last 2 quarters. The consolidated Non-GAAP combined ratio improved from 112.2% in 2025-Q1 to 109.9% in 2026-Q1, and Specialty P&C segment improved from 109.0% to 105.9%. Operating income increased but remains challenged. The trajectory shows progress in underwriting profitability consistent with management's stated focus.
“Consolidated Non-GAAP combined ratio improved to 109.9%, Specialty P&C Non-GAAP combined ratio 105.9%.”
“Consolidated Non-GAAP combined ratio for full-year 2025 improved to 104.2%, Specialty P&C Non-GAAP combined ratio 98.3%.”
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a mixed scenario with fragile earnings quality and weak recent performance. The current thesis state suggests caution, as the company has not shown strong execution despite a favorable sector backdrop.
The market appears to have priced in a level of fragility in PRA's earnings, reflecting weak execution quality. The valuation is considered expensive compared to peers, indicating that expectations may be high relative to the company's recent performance.
Fundamentals may remain weak in the near term, as recent financial performance has not met industry standards. Management has set priorities that show mixed results, which could impact future earnings stability.
The thesis hinges on the performance of sector bellwethers like CB, PGR, and TRV. If these companies continue to perform well, it could provide a tailwind for PRA, but any signs of weakness could lead to further challenges.
Over the next 1 to 3 years, PRA's performance will depend heavily on sector trends and management execution. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The latest earnings miss is a key factor. This miss shows ongoing struggles in financial performance. The company is still below typical for its sector.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.